

Patient: Iwont Heal
Patient ID: AB07-22-88*04267
Home Phone: 111.111.1111

DOB: 07/31/1960
Age: 57
Gender: Male


Accession: 00011
Provider: Dr. Doctor, MD
Collected: 08/06/2018 11:15AM

Wound Test Report

Sample Source: Right Foot, 1st Digit

Positive Summary

Classification	Genus Species	Result	Relative Amount
Aerobic Bacteria: Gram Positive	Methicillin Resistant Staphylococcus aureus (MRSA)	Positive	80
Aerobic Bacteria: Gram Negative	Klebsiella pneumonia	Positive	20
Antibiotic Resistance	Extended Spectrum beta Lactamase (ESBLs): SHV	Positive	N/A



Therapeutic Options:

Methicillin Resistant Staphylococcus aureus (MRSA)

Oral:

Clindamycin 300-450mg PO three times a day
Doxycycline 100mg PO twice daily
Linezolid 600mg PO twice daily

Parenteral:

IV antibiotics generally not needed unless severe infection, concomitant bacteremia or systemic toxicity.

Vancomycin 15mg/kg IV q12hours
Clindamycin 600mg IV q8hours
Linezolid 600mg IV q12hours
TMP/SMX 8-12mg/kg (based on TMP) divided dosing q6hours IV

Note: Duration of therapy: depends on extent of disease, usual range 5-10 days.

Klebsiella pneumonia

Oral:

Amoxicillin/Clavulanate 500mg PO q8-12h or 875mg q12h
Levofloxacin 250mg PO QD
TMP/SMX (DS) 1-2 PO q12h x5-10d

Parenteral:

Imipenem/Cilastatin 500mg IV q6h
Ceftaroline 600mg IV q12

ESBL Severe infections or concern

Ertapenem 1 g IV q24h (avoid in severe infections)
Meropenem 1-2 g IV q8h

TMP/SMX 1-2 DS tabs PO twice daily
Minocycline 100mg PO twice daily

Daptomycin 4mg/kg IV daily
Ceftaroline 600mg IV q12hours
Tedizolid 200mg IV q24hours

Cefprozil 250-500mg q12 or 500mg qd x10 days
Ciprofloxacin 250mg PO BID
Delafloxacin 450mg PO q12h for 5 to 14 days

Ceftazidime 0.5-1g IV or IM q8h

Imipenem 500 mg IV q6h

TEST

AEROBIC BACTERIA: GRAM POSITIVE

Enterococcus faecalis
Enterococcus faecium
Methicillin Sensitive Staphylococcus aureus (MSSA)
Methicillin Resistant Staphylococcus aureus (MRSA)

RESULT

Run by: SR on 08/08/2018 11:00 AM

Negative
Negative
Negative
Positive

Patient: Iwont Heal
Patient ID: AB07-22-88*04267
Home Phone: 111.111.1111

DOB: 07/31/1960
Age: 57
Gender: Male

Accession: 00011
Provider: Dr. Doctor, MD
Collected: 08/06/2018 11:15AM

Methicillin Resistant Staphylococcus epidermidis (MRSE)
Mycobacterium fortuitum
Staphylococcus epidermidis
Streptococcus agalactiae (Group B Strep)
Streptococcus dysgalactiae (Group C Strep)
Streptococcus pyogenes (Group A Strep)

Negative
Negative
Negative
Negative
Negative
Negative

AEROBIC BACTERIA: GRAM NEGATIVE

Acinetobacter baumannii
Bacteroides fragilis
Bartonella henselae
Bartonella quintana
Citrobacter freundii
Enterobacter aerogenes
Enterobacter cloacae
Escherichia coli
Klebsiella oxytoca
Klebsiella pneumoniae
Morganella morganii
Proteus mirabilis
Pseudomonas aeruginosa

Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Positive
Negative
Negative
Negative

ANAEROBIC BACTERIA: GRAM NEGATIVE

Prevotella intermedia

Negative

ANTIBIOTIC RESISTANCE

Carbapenem

KPC
NDM-1

Negative
Negative

Extended Spectrum Beta-lactamase

CTXM
CYM
ESBL
SHV
TEM

Negative
Negative
Positive
Negative
Negative

Vancomycin Resistance

VanA/VanB

Negative

Macrolide-Lincosamide-Streptogramin B Resistance

ermA
ermB

Negative
Negative

Staphylococcus Virulence Gene

lukF-PV (Panton-Valentine Leukocidin, PVL)

Negative

Patient: Iwont Heal
Patient ID: AB07-22-88*04267
Home Phone: 111.111.1111

DOB: 07/31/1960
Age: 57
Gender: Male

Accession: 00011
Provider: Dr. Doctor, MD
Collected: 08/06/2018 11:15AM

FUNGI

Candida albicans

Negative

Candida dubliniensis

Negative

Candida glabrata

Negative

Candida parapsilosis

Negative

Candida tropicalis

Negative

Advanced Pathology Solutions Wound Test utilizes DNA sequencing of targeted unique gene regions to determine the presence of each of the bacteria, bacterial antibiotic resistance genes and fungi detected by the assay. The test is a laboratory developed test (LDT) developed and validated by Advanced Pathology Solutions to detect the specific targets reported. Other bacteria, bacterial antibiotic resistance genes and fungi may be present in a clinical sample. The reported test results should be interpreted in relation to each patient's clinical condition and medical history. Treatment options presented are for informational purposes only. The Advanced Pathology Solutions Wound Test is not cleared by the US Food and Drug Administration (FDA) and clearance is not currently required for LDTs. Regulatory oversight of the Wound Test high complexity clinical test at Advanced Pathology Solutions is administered by the Centers for Medicare Services (CMS) - Clinical Laboratory Improvement Amendment (CLIA) of 1988.